Circulating Tissue Inhibitor of Matrix Metalloproteinase-4 (TIMP-4) in Systemic Sclerosis Patients with Elevated Pulmonary Arterial Pressure

Table 2

Pulmonary function tests (mean ± SD of % predicted, number of patients with less than 80% of predicted) in patients with systemic sclerosis (SSc).

	All patients	Diffuse SSc	Limited SSc
	(𝑛 = 106)	(𝑛 = 75)	(𝑛 = 31)
FEV1	86 ± 17, 32	86 ± 18, 26	88 ± 16, 6
FVC	87 ± 19, 31	87 ± 20, 25	90 ± 16, 6
TLC	80 ± 16, 46	79 ± 16, 34	81 ± 17, 12
DLCO	68 ± 21, 81	67 ± 22, 54	69 ± 19, 27

FEV1: forced expiratory volume at 1 second;FVC: forced vital capacity;TLC: total lung capacity;DLCO: diffusing lung capacity for carbon monoxide.